PsyBio Therapeutics Increases Intellectual Property Portfolio with Filing of Novel Genetic Optimization Pathways for… May 12, 2021
PsyBio and Miami University Broaden Partnership Agreement to Continued Advancement of its Neuropsychiatric Drug… Apr 26, 2021
PsyBio Therapeutics Appoints Pharmaceutical Veteran Bob Oliver to its Board of Directors Apr 21, 2021
PsyBio Therapeutics Retains KCSA Strategic Communications for Investor Relations Services Apr 9, 2021
PsyBio Therapeutics Initiates Process Development of Proprietary Biosynthetic Norbaeocystin Mar 23, 2021
